ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data…
Transparency Notification from Shareholder Ghent, Belgium – 13 October 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or…
SEOUL, South Korea, Sept. 26, 2025 /PRNewswire/ -- JNH PRESS, a leading Korean press manufacturer, celebrated a major milestone with…
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation The fund…
Availability of the Q3 2025 Aide mémoire Paris, France – September 24, 2025. Sanofi announced today that its Q3 2025…
PRESS RELEASE - 09/15/2025, 09:00 AM EDT Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test First-ever fully automated,…
The 2025 Carnival MPV and 2025 Telluride SUV each received 2025 Winter Vehicle Awards from the New England Motor Press…
Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of…
Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase…
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Ghent, Belgium, 22 July 2025 – Sequana Medical…